In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes ...

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically ...

Exegenesis Bio provided an update on the company’s treatment candidates for wet age-related macular degeneration (wet AMD). EXG102 is an investigational gene therapy for wet AMD that is administered ...

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This ...

Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting ...

DelveInsight has released a report entitled, “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.″ This report is a detailed look at diabetic macular edema (DME) ...